Your session is about to expire
← Back to Search
ACE inhibitor/ARB
Continuation of ACEi and/or ARBs for Chronic Kidney Disease
N/A
Waitlist Available
Led By Raymond Hsu, MD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up months 1-12
Awards & highlights
Study Summary
This trialseeks to determine the safety & feasibility of ACEi/ARB use for advanced CKD. Current guidelines lack evidence to support benefit of use in this group.
Eligible Conditions
- Chronic Kidney Disease
- High Blood Pressure
- ACE Inhibitors
- Angiotensin Receptor Blockers
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ months 1-12
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~months 1-12
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of all cause emergency room visits
Number of all-cause hospitalizations
Number of falls and syncope reported by patients and/or discharge summaries
+3 moreTrial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: ACEi/ARB continuationExperimental Treatment1 Intervention
Intervention group will continue or start to take ACEi and/or ARBs
Group II: ACEi/ARB withdrawalActive Control1 Intervention
The control group will discontinue ACEi and/or ARBs which may be substituted with other anti-hypertensive agents (if already taking ACEi/ARB) or continue to not take ACEi/ARBs
Find a Location
Who is running the clinical trial?
University of California, San FranciscoLead Sponsor
2,491 Previous Clinical Trials
11,930,580 Total Patients Enrolled
Raymond Hsu, MDPrincipal InvestigatorUniversity of California, San Francisco
Elaine Ku, MDPrincipal InvestigatorUniversity of California, San Francisco
2 Previous Clinical Trials
20 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You don't want to agree to participate in the study.You are currently using illegal drugs or drinking alcohol excessively.You have problems with your memory or thinking that would make it difficult for you to take part in the study.You are already taking part in another study that may impact your blood pressure.
Research Study Groups:
This trial has the following groups:- Group 1: ACEi/ARB continuation
- Group 2: ACEi/ARB withdrawal
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are recruitment efforts underway for this trial?
"Clinicaltrials.gov affirms that this medical trial, which was first posted on September 7th 2023 and last updated on October 31st 2022, is not presently enrolling participants. However, 600 other trials are open to candidates at present."
Answered by AI
Share this study with friends
Copy Link
Messenger